Patent Application
20120077860
This invention relates to the use of adeno-associated viral vectors, or AAV vectors, to deliver antisense sequences, directed against splice sites of a gene encoding a dispensable domain protein, to target cells, and the therapeutic applications of this, in particular in the treatment of Duchenne muscular dystrophy.
Thus, carefully chosen sequences introduced into a vector according to the invention are capable of resulting in transcripts producing a shorter but functional dystrophin protein, correcting certain forms of Duchenne muscular dystrophy.
Duchenne muscular dystrophy (DMD) is a genetic disease carried on the X chromosome, which affects about 1 boy in 3,500. It is characterised by the absence of a 427 kilodalton protein, cytoskeletal dystrophin, which results in the death of muscle fibres, correlated with progressive severe muscle deterioration.
Dystrophin is a modular protein with a central region composed of 24 spectrin-like repeated domains. Proteins lacking certain of these repeated sequences can however be perfectly functional or at least only partially defective, as observed in attenuated forms of DMD (Becker dystrophy).
On the other hand, the majority of serious mutations of the dystrophin gene consist of deletions of one or more exons perturbing the final messenger's reading frame or point mutations, present in the encoding regions or exons, which introduce stop codons or shift the reading phase. In both cases, these mutations result in the absence of dystrophin.
As an illustration, a large number of clinical cases of Duchenne muscular dystrophy are linked to multi-exon deletions (severe DMD genotypes: Δ45-50; Δ47-50; Δ48-50; Δ49-50; Δ50; Δ52) where the reading frame could be re-established by deleting exon 51 (mild BMD genotypes: Δ45-51; Δ47-51; Δ48-51; Δ49-51; Δ51-52).
Different strategies and techniques have been envisaged to attempt to “repair” the mutated dystrophin genes.
Replacing the dystrophin gene in affected muscle fibres, or compensating for necrosed cells by healthy cell grafts, has revealed major difficulties.
The third route envisaged, currently the most used, consists of attempting to repair the mutated DNA using antisense oligonucleotides (or AON) allowing certain exons to be skipped, thus to arrive at the expression of a truncated but functionally effective protein. This so called “exon skipping” technique involves the use of oligonucleotides which are complementary to the sequences involved in splicing the exon to be masked.
Current studies in this direction are essentially being carried out in mdx mice which have this disease, because of a nonsense mutation introducing a stop codon in exon 23 of the murine dystrophin gene.
The main difficulty of this technology lies in introducing a non-degraded oligonucleotide (AON) in a stable and sustainable manner into diseased muscle fibres, particularly in vivo.
In the first instance, directly injecting the said oligonucleotides was envisaged, possibly in combination with a synthetic detergent, such as the agent F127. Advantageous sequences to be administered by this route to mask exon 19 or 45 of the human dystrophin gene are for example thus described in patent applications EP 1054058 and EP 1191098, respectively. However, in view of the short life span of these oligonucleotides in muscle, this method of treatment requires regular, relatively restricting injections.
In addition, attempts have been made to introduce these sequences into vectors to carry them into the target cells. To date, only in vitro trials have been carried out: the constructions used are based on the use of retroviruses and have been tested only on cell cultures. The results reported have not proved to be very convincing, or at least insufficient to envisage an in vivo transposition.
For example, the document WO 02/24906 illustrates the use of these two distinct methods to exclude exon 46 in human cells.
All of the work carried out on vector transfer of AON has mainly shown that:
The presence of small snRNA (small nuclear RNA) type sequences allows better translocation into the nucleus of target cells and better transcription of sequences. The document WO 03/095647 thus advocates the advantages of selecting U2 and U3 snRNA.
However, at present no solution has been proposed for skipping exons in vivo, with the exception of injecting oligonucleotides with the disadvantages indicated above.
For the first time, the inventors propose a construction producing in vivo results which are remarkable as far as restoring dystrophin protein activity is concerned in Duchenne muscular dystrophy.
In addition, these results obtained on dystrophin could be extended to any dispensable domain protein. It could also concern all multi-exon genes encoding a dispensable domain protein where the deletion (by exon skipping) does not affect or little affects the activity of the protein.
In regard to this, the invention proposes to construct an adeno-associated viral vector comprising:
In the rest of the description, the combination composed of these three entities (an snRNA sequence/U7 promoter/antisense sequence or sequences) is called the “U7 cassette”.
Among the multitude of available vectors, the applicant has selected to advantage a vector of viral origin, namely an adeno-associated virus derivative or AAV. Among the 8 identified serotypes, the AAV used in the particular context of DMD is preferably an AAV1, i.e. it has a serotype 1 capsid. Indeed, AAV1 most effectively transduces muscle cells.
On the other hand, the original viral sequences, in particular ITRs associated with the transgene are to advantage from AAV2. The result is that, in an advantageous embodiment, the final adeno-associated viral vector is a 2/1 pseudotype.
The said vector also contains a modified snRNA sequence. Small nuclear RNAs, or snRNAs, are RNAs of small size present in the nucleus of cells and implicated in certain stages of maturation of pre-mRNAs. They are called U1, U2 . . . U10.
Among these different types of snRNA, type U7, normally involved in the maturation of premessenger RNAs encoding histones, is preferentially used as transporter.
The snRNAs in question may be of human or murine origin in as far as these small sequences are highly conserved between the different species. Preferentially, the snRNA used in the invention is that of the mouse.
“Modified snRNA” means an RNA in which the sequences involved in the initial function of the snRNA are inactivated. These sequences may also be modified in such a way as to increase the level of expression of the said snRNA.
For example, in the case of U7, the sequence of the fixation site of the “small nuclear ribonucleoprotein” (or Sm protein) is modified so as to inactivate the maturation of premessenger RNAs encoding the histones and to increase in parallel the nuclear concentration of U7snRNA. Moreover, the sequence of 18 complementary nucleotides at the 3′ maturation site of premessenger RNAs encoding the histones is replaced by the antisense sequences of interest.
In practice, these modifications can be introduced by site-directed mutagenesis using PCR.
The snRNA gene thus modified is then cloned in the AAV vector, preferably between its two ITR sequences.
This invention may also be carried out with U1 or U2 sequences, but with more modifications and a less effective result.
A vector according to the invention also includes a promoter allowing antisense sequences to be expressed at a sufficient level to ensure their biological and therapeutic activity. Numerous usable promoters in the context of AAVs are known to those skilled in the art. However, in a preferred embodiment of the invention, the expression of the antisense sequences is controlled by the native promoter of the snRNA used in the construction. Where U7 is preferred, it is thus the U7 promoter which transcribes the antisense sequences.
The vector according to the invention also includes at least one antisense sequence directed against at least one splice site of at least one exon (i.e. capable of interfering with the splicing of the said exon). The antisense sequence is preferentially a complementary sequence with at least one sequence chosen from the following group: 5′ splice site (donor); 3′ splice site (acceptor); BP (Branching Point) intronic sequence; and possibly purine-rich internal regions, more specifically ESEs (Exon-internal Splicing Enhancers).
Advantageously, to ensure the exclusion of a given exon, two antisense sequences with distinct targets, preferentially the 5′ donor site and the BP sequence, are introduced in a single recombinant vector according to the invention.
Antisense sequences directed against splice sites of at least two distinct exons may also be associated in the same construction.
Alternately, it is possible to use several constructions, each carrying a distinct antisense sequence, the said sequences being directed against one or more exons.
In practice, when several antisense sequences are combined (directed against the same exon or several different exons), the following situations can arise:
In the context of the invention, the antisense sequences are specific to the different splice sites of exons forming the dystrophin gene, whatever its origin.
The murine dystrophin gene is of obvious interest as the mouse is an experimental animal model of choice. Thus, an mdx mouse, with a mutation in exon 23 of the murine dystrophin gene producing an inactive truncated protein, shows the symptoms of DMD. In this context, the antisense sequences are directed therefore against the sequences involved in splicing exon 23.
More particularly, a vector according to the invention includes an SEQ ID 1 sequence consisting of a U7snRNA gene modified as described above and integrating antisense sequences directed against the 5′ donor site (SEQ ID 2) and the BP sequence (SEQ ID 3) of exon 23 of the murine dystrophin gene placed under the control of the U7 promoter, introduced between the 2 ITR sequences of the AAV vector.
Very interestingly, the functionality of such vectors has been validated by the applicant in a large animal, the dog. There are indeed dogs that are naturally myopathic because of a mutation in the splice acceptor site of intron 6 such that the fact that exon 7 is not taken into account in the final mRNA nullifies the reading frame, exons 6 and 8 not being in phase. Theoretically an operational reading frame can be restored by simultaneously skipping exons 6 and 8, the final mRNA being thus deprived of exons 6, 7 and 8. The association of vectors according to the invention, including the antisense sequences SEQ ID 27 and 28, directed against ESE regions of exons 6 and 8 respectively, has thus proved effective.
For treatment in humans, the antisense sequences selected are directed against at least one splice site of at least one exon of the human dystrophin gene, the exclusion of which produces a truncated but active protein.
As previously discussed, exon 51 of the human dystrophin gene, and more particularly the sequences involved in its splicing, are advantageous targets in the context of the invention. Thus, excluding it from the transcript encoding dystrophin may be beneficial in the treatment of about 20% of the clinical cases today recorded as genotyped for Duchenne muscular dystrophy.
It has been shown by the inventors that a suitable construction of the invention comprised the sequence SEQ ID 4, associating two antisense sequences SEQ ID 5 and SEQ ID 6 directed against purine-rich internal regions of exon 51 of the human dystrophin gene, in place of sequences SEQ ID 2 and 3 in the sequence SEQ ID 1.
Other human antisense sequences that can be used in the context of the invention are as follows:
These sequences are preferentially combined in tandem in a vector according to the invention. Preferentially, DA5′ (SEQ ID 7) and DA3′ (SEQ ID 8) or G5′ (SEQ ID 9) and GBP (SEQ ID 10) are combined.
Sequences SEQ ID 25 and SEQ ID 26 correspond to the longer sequences SEQ ID 5 and SEQ ID 6. They are preferentially combined. Given their large size, each is advantageously integrated in a U7 cassette, carried either by the same AAV vector, or by two distinct AAV vectors used in tandem.
Very interestingly, the applicant has shown in this invention that the nature of the antisense sequence could play an important role in the efficacy of the construction and also that it was possible to evaluate the efficacy of these sequences by in vitro experiments on target muscle cells by transposing the said U7 cassettes in a lentiviral vector.
The invention thus also concerns a lentiviral vector comprising:
The applicant has shown that such a vector is effective in skipping the human exon 51, considerably more so than seen with the construction of De Angelis et al. (1). For the first time, the unequivocal production of dystrophin in vivo is reported, after the injection of patient cells (delta 49-50) genetically modified using a lentiviral vector according to the invention into SCID-mdx mice.
Preferentially, the lentiviral vector replacing the adeno-associated viral vector according to the invention is an SIN (self inactivating) lentivirus of the latest generation. Nevertheless, any lentiviral vector may to be used to insert a U7 cassette. The construction and manipulation of lentiviral vectors is well known to those skilled in the art.
These lentiviral vectors have applications which are complementary to those of recombinant AAVs according to the invention. While the latter are intended to be injected in situ in the target muscles, with lentiviral vectors the efficacy of potential antisense sequences can be tested in vitro, directly in differentiated muscle cells from the patient to be treated. Secondly, if these vectors are introduced into myoblasts, muscle precursors, or even stem cells, in situ grafting of transfected cells can be envisaged.
Any type of cell transfected by the recombinant vector is therefore also part of the invention, particularly muscle cells and in particular muscle fibre types (myotubes), muscular precursors (myoblasts) or any cell capable of muscular differentiation.
Any muscular tissue or non-human organism transfected by the said vector is also included within the scope of the protection sought. Among non-human organisms, animals—in particular mice—are preferred.
This application describes for the first time a therapeutic potential for the vectors claimed. This invention thus also concerns pharmaceutical compositions including at least one vector as defined in this application as an active component, as well as the use of this vector as a medicinal product. In addition, as indicated above with reference to lentiviral vectors, transfected cells may also have therapeutic potential in the context of grafts.
A pharmaceutical composition according to the invention contains the vector or the cells claimed, associated with a pharmaceutically acceptable, inert vehicle.
When vectors according to the invention are to be injected into diseased muscles, the pharmaceutical composition will preferably be in liquid form. The vector concentration, the quantity to be injected and the frequency of injections are easily determined by those skilled in the art.
In view of the remarkable effects seen in vivo on restoring dystrophin in muscle fibres affected by DMD, a claim is also made for using the vector or cells according to the invention to prepare a medicinal product intended for the treatment of Duchenne muscular dystrophy.
More generally, a vector according to the invention may be used for the treatment of any disease associated with dysfunction of a dispensable domain protein where skipping at least one exon encoding a dispensable domain can restore its function.
Apart from the dysfunction of dystrophin associated with Duchenne muscular dystrophy illustrated here, certain myopathies are linked for example to dysfunction of the dispensable domain protein dysferlin and could therefore be treated with a vector according to the invention.
During in vivo use, vectors according to the invention proved to be stable, to have a specific sub-cellular location and permanently produce therapeutically active quantities of antisense.
More generally, this application demonstrates the potential of the AAV-U7snRNA system as a tool for inactivating or modifying mRNA in animals.
The invention and the advantages resulting from it are better illustrated by the following embodiments and the attached figures.
1. Constructions
The entire U7 snRNA gene (445 bp) was obtained by PCR on the genomic DNA of the mouse with the oligonucleotides: 5′-TAACAACATAGGAGCTGTG-3′ (SEQ ID 14) and 5′-CAGATACGCGTTTCCTAGGA-3′ (SEQ ID 15). The Sm domain (AATTTGTCTAG; SEQ ID 16) was optimised to smOPT (AATTTTTGGAG; SEQ ID 17), as described previously (3), and the U7 region capable of matching with the pre-mRNA was exchanged with a sequence of 44 complementary nucleotides both in the region covering the BP (branch point) sequence before exon 23 of the dystrophin gene (BP22: 5′-AAATAGAAGTTCATTTACACTAAC-3′; SEQ ID 3) and the region after the splice donor site (SD23: 5′-GGCCAAACCTCGGCTTACCT-3′; SEQ ID 2). The resulting U7smOPT-SD23/BP22 fragment was then inserted between 2 inverse terminal repeat sequences of AAV2 (SEQ ID 1).
2. Vectors
AAV2/1 pseudotype recombinant vectors were prepared in 293 cells, as already described (4), by cotransfecting 3 plasmids: pAAV2 (U7smOPT-SD23/BP22) encoding the genome rAAV2, pXX6 bearing the adenovirus helper functions and pAAV1p1TRCO2 which supplies the rep and cap genes of AAV1. The concentrations of vectors varied between 1012 and 1013 vector genomes (vg) ml−1.
3. Animals and Delivery Methods
All the animal procedures were carried out according to the protocol approved by the institution and under strict conditions of biological containment. A first group of mdx mice (8 weeks old) received injections of 50 μl PBS (phosphate buffered saline) containing 1012 (vg) AAV (U7-SD23/BP22) into the tibialis anterior muscle of the right rear leg. The contralateral muscles were used as controls. A second group of mdx mice of the same age were subjected to an intra-arterial infusion of 2×1013 vectors via the femoral artery. The mice were sacrificed at given times, the muscles were frozen in isopentane cooled by liquid nitrogen and stored at −80° C.
4. Histology
Serial transverse sections (8 μm), made at 200 μm intervals along the length of the muscle, were examined for dystrophin (NCL-DYS2; murine monoclonal antibodies against the C-terminal domain; Novocastra) and the proteins associated with dystrophin (β-dystroglycan, α and β-sarcoglycan; Novocastra) by immunological detection, according to the manufacturer's instructions. The monoclonal antibodies were detected with biotinylated antibodies followed by avidin-FITC (M.O.M. Kit, Vector Laboratories). The sections prepared were analysed by laser scanning confocal microscopy (Leica). Intermediate tissues were collected for later analyses of proteins and RNA.
5. Analysis by Immunological Detection
The sections of the intermediate layers were collected and extracted with a lysis buffer containing 4% SDS, 125 mM Tris-HCl pH 6.4, 4 M urea, 10% β-mercaptoethanol, 10% glycerol, 0.001% bromophenol blue. After separation by centrifuging, the protein content was measured using the Bio-Rad Protein Assay test. The samples, adjusted to 40 μg of proteins, were loaded onto 6% polyacrylamide gels, subjected to electrophoresis and transferred onto nitrocellulose membranes which had been incubated with either NCL-DYS1 (murine monoclonal antibodies against the R8 repeated sequence of the spectrin-like rod domain of dystrophin; Novocastra) or NCL-DYS2, diluted to 1:100, followed by incubation with horseradish peroxidase conjugated secondary antibodies (1:1000) and analysis using the ECL Analysis System (Amersham).
6. RNA Analysis
The total RNA was isolated from a pool of intermediate sections using the reagent TRIzol (Life Technologies). To detect U7 and U7smOPT-SD23/BP22, reverse transcription was first of all carried out on the total RNA with Superscript II reverse transcriptase, in the presence of random hexamers (Invitrogen). Then, the cDNAs were amplified using Taq polymerase (Promega) with 5′-AAGTGTTACAGCTCTTTTAG-3′ (SEQ ID 18 located in the wild U7) or 5′-AAGGCCAAACCTCGGCTTAC-3′ (SEQ ID 19 located in U7smOPT-SD23/BP22) and 5′-AGGGGTTTTCCGACCGAAG-3′ (SEQ ID 20) for 30 cycles (94° C./30 s; 55° C./30 s; 72° C./30 s). The PCR products were analysed on 2% agarose gels. To detect the dystrophin mRNA, nested RT-PCR was carried out with 200 ng of total RNA. The first reaction occurred with the primers Ex20ext (SEQ ID 21; 5′CAGAATTCTGCCAATTGCTGAG-3′) and Ex26ext (SEQ ID 22; 5′-TTCTTCAGCTTGTGTCATCC-3′) in 30 cycles (94° C./30 s; 55° C./1 min; 72° C./2 min). Then 2 μl of the first reaction were amplified in 23 cycles with Ex20int (SEQ ID 23; 5′-CCCAGTCTACCACCCTATCAGAGC-3′) and Ex26int (SEQ ID 24; 5′-CCTGCCTTTAAGGCTTCCTT-3′). The PCR products were analysed on 2% agarose gels and the specific bands were purified for sequence analysis.
7. Physiology of the Muscle
The extensor digitorum longus muscles (EDL) of control or treated mice were dissected to assess their contractile/mechanical properties. The isolated muscles were connected on one side to an electromagnetic puller and on the other side to a force sensor, and were stimulated using electrodes placed parallel to the muscle. The tonic isometric contractions linked to a brief shock (125 Hz; 360 ms, separated by resting periods of 3 min) were studied at L0 (the length at which the maximum isometric tonic force was observed). The isometric tension was calculated by dividing the force by the estimated cross-sectional area (CSA) of the muscle. Supposing that the muscles were cylindrical in shape and had a density of 1.06 mg.mm−3, the CSA corresponds to the wet weight of the muscle divided by the length of its fibres (5). Eccentric contractions induce muscle damage related to membrane rupture in a characteristic manner. They occur when a maximally contracted muscle is forcibly stretched, which leads to a loss of force. Here, the muscles were elongated by 10% of the length L0 for which the muscle produced a maximum force at a speed of 1 fibre length per second. Five eccentric contractions were applied at 3 minute intervals. The accumulated decline in isometric force was quantified as previously described (5).
A U7 type RNA was modified in order to introduce antisense sequences into it which would interfere with the messenger RNA (mRNA) maturation process in the nucleus. The U7snRNA sequence was optimised to transport antisense sequences directed against introns 22 and 23 of the murine dystrophin gene. The sequences in intron 22 were chosen to compete with the fixation of U2snRNA at the BP (Branching Point) splice site (BP22; SEQ ID 3), and sequences in intron 23 corresponding to the fixation site of U1 at the donor site (SD23; SEQ ID 2) (
The modified U7 gene, including both the promoter and the 3′ elements, was put into a construction based on AAV-2, which was introduced into the AAV-1 capsid to obtain high transfer efficiency for the transfer of genes into skeletal muscles. Adult mdx mice (8 weeks old) received a single dose of 1010 vector genomes by injection into the tibialis anterior muscle and were analysed at various times between 2 and 16 weeks. Molecular analysis of the skipping of exon 23 was done by nested RT-PCR on the total RNA prepared from the muscles injected. A shorter transcript, lacking exon 23, was detected. It represented 5 to 10% of the amplified material 2 weeks after injection and became the majority type after a month (
In line with the generation of transcripts which had undergone exon skipping, the dystrophin protein was detected both by immunodetection in muscle extracts and by immunofluorescence on tissue sections (
A group of mdx animals received the AAV-U7 vector by high-pressure intra-arterial perfusion in the lower limb. After a month this resulted in effective restoration of dystrophin in most fibres, in all the muscles of the perfused limb, including the TA and EDL muscles (
The susceptibility to damage induced by exercise was assessed in treated animals by measuring the resistance to tonic contractions followed by forced elongation. For this experiment, the mice received a single dose of AAV-U7 into the EDL muscle and were analysed after 45 days. While the muscles of mdx animals were incapable of withstanding repeated elongations, the treated muscles expressing dystrophin restored in more than 70% of their fibres essentially performed in a way equivalent to normal muscles with a loss of force of 17% following 5 stimuli, compared with 15% for the wild type (
The results obtained in the mouse could be transposed to a large animal, the GRMD dog. The GRMD dog has a point mutation in the splice acceptor site of intron 6 (AG transformed into GG;
Two U7 type RNAs were modified in order to introduce antisense sequences into them which would interfere with the splicing mechanism in the region of exons 6 and 8 (
The efficacy of AAV (U7-ex6) vectors integrating the antisense sequence SEQ ID 27 and AAV (U7-ex8) integrating the antisense sequence SEQ ID 28 was tested in vivo by local/regional injection in adult GRMD subjects.
We have developed an approach in which cell therapy and exon skipping can be combined in populations of cells capable of participating in muscle regeneration in vivo. To do this, we have developed lentiviral vectors carrying U7 cassettes to induce therapeutic skipping (murine, canine and human models).
As an example, we describe below the restoration of dystrophin in the cells of a DMD patient with deletion of exon 49-50.
Different Lenti (U7ex51 human) vectors were produced, one of them carrying the sequences previously described by De Angelis (1) (
Circulating AC133+ stem cells (20×104) freshly obtained from a DMD patient (delta 49-50) were transduced by the Lent (U7-H51ab) vector integrating the antisense sequences SEQ ID 5 and SEQ ID 6, and rapidly reinjected into the tibialis anterior muscles of SCID-mdx mice, with the intention of proving the possibility of therapeutic exon skipping in vivo using cells from DMD patients.
Histological analysis, one and a half months later, conclusively demonstrated the restoration of human dystrophin (revealed using DYS3 antibodies not crossing with the murine dystrophin) in numerous, probably man/mouse chimeric, muscle fibres (
| Number | Date | Country | Kind |
|---|---|---|---|
| 0451861 | Aug 2004 | FR | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/FR05/50642 | 8/2/2005 | WO | 00 | 2/16/2007 |
